BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 39 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $7,000 | – | 13,616 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cypress Point Wealth Management, LLC | 1,887,509 | $3,869,000 | 3.93% |
| Naviter Wealth, LLC | 1,571,107 | $3,221,000 | 1.08% |
| ARMISTICE CAPITAL, LLC | 5,500,000 | $11,275,000 | 0.22% |
| INVERNESS COUNSEL LLC /NY/ | 1,210,537 | $2,482,000 | 0.11% |
| Allegheny Financial Group LTD | 11,595 | $24,000 | 0.01% |
| BALDWIN BROTHERS LLC/MA | 38,604 | $79,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 137,700 | $282,000 | 0.01% |
| Rafferty Asset Management, LLC | 46,268 | $95,000 | 0.00% |
| TWO SIGMA SECURITIES, LLC | 15,388 | $32,000 | 0.00% |
| Renaissance Technologies | 582,392 | $1,194,000 | 0.00% |